首页> 外文期刊>Pharmaceutical Research >A Novel Peptide Nanomedicine Against Acute Lung Injury: GLP-1 in Phospholipid Micelles
【24h】

A Novel Peptide Nanomedicine Against Acute Lung Injury: GLP-1 in Phospholipid Micelles

机译:一种针对急性肺损伤的新型肽纳米药物:磷脂胶束中的GLP-1。

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Treatment of acute lung injury (ALI) observed in Gram-negative sepsis represents an unmet medical need due to a high mortality rate and lack of effective treatment. Accordingly, we developed and characterized a novel nanomedicine against ALI. We showed that when human glucagon-like peptide 1(7–36) (GLP-1) self-associated with PEGylated phospholipid micelles (SSM), the resulting GLP1-SSM (hydrodynamic size, ~15 nm) exerted effective anti-inflammatory protection against lipopolysaccharide (LPS)-induced ALI in mice.
机译:目的在革兰氏阴性脓毒症中观察到的急性肺损伤(ALI)治疗由于高死亡率和缺乏有效的治疗方法而未能满足医疗需求。因此,我们开发并表征了针对ALI的新型纳米药物。我们显示,当人胰高血糖素样肽1(7–36)(GLP-1)与PEG化磷脂微团(SSM)自缔合时,所得的GLP1-SSM(流体动力学大小,约15 nm)发挥了有效的抗炎保护作用抗脂多糖(LPS)诱导的小鼠ALI。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号